Researchers have confirmed that blocking an immune checkpoint molecule reduces tumor size and prolongs survival in animal models of the most aggressive childhood cancer. This study, carried out by researchers from Cima and the Clínica Universidad de Navarra, together with the international cooperative group Diffuse Midline Glioma (DMG-ACT), shows that inhibition of TIM-3 promotes the immune memory of diffuse intrinsic stem glioma (DIPG) and improves the prognosis of the disease.
Blocking immune molecule reduces tumor growth, prolongs survival of most aggressive childhood cancer in animal models
Researchers have confirmed that blocking an immune checkpoint molecule reduces tumor size and prolongs survival in animal models of the most aggressive childhood cancer. This study, carried out by researchers from Cima and the Clínica Universidad de Navarra, together with the international cooperative group Diffuse Midline Glioma (DMG-ACT), shows that inhibition of TIM-3 promotes the immune memory of diffuse intrinsic stem glioma (DIPG) and improves the prognosis of the disease.